Henrik Kjaer Hansen

Director/Board Member at WCG CLINICAL, INC.

50 year

Health Technology

Finance

Consumer Services

Profile

Henrik Kjaer Hansen is currently Director at Sonion A since 2022.
Mr. Hansen is Independent Director at WCG Clinical, Inc. since 2020.
Mr. Hansen is Senior Partner at Novo Principal Investments since 2017.
Mr. Hansen is Senior Partner at Novo Holdings A since 2017.
Former positions include Independent Director at Orexo AB from 2018 to 2023, Director at Xellia Pharmaceuticals AS, and Senior Vice President at Moelis & Company UK LLP.
Education includes undergraduate and graduate degrees from Copenhagen Business School.

Henrik Kjaer Hansen active positions

Companies	Position	Start
WCG CLINICAL, INC.	Director/Board Member	2019-12-31
Novo Holdings A/S (Investment Company) Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings-IC aims to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. The firm invests in almost all life science segments including pharmaceuticals, biotechnology, medical technology, healthcare services and industrial BioSolutions. Outside of the life sciences they invest in a diversified portfolio of equities, fixed income, real assets and alternatives.	Chief Investment Officer	2017-11-30
Novo Principal Investments Novo Principal Investments Investment ManagersFinance Novo Principal invests in public and private companies located across Europe and North America. The firm focuses on companies operating in the fields of healthcare and life science sectors. It provides financing for later stage capital requirements.	Private Equity Investor	2016-12-31
Sonion A/S Sonion A/S Medical SpecialtiesHealth Technology Design and manufactures micro-acoustic and micro-mechanical components for hearing instruments, in-ear earphones and earphones	Director/Board Member	2022-05-09

All active positions of Henrik Kjaer Hansen

Former positions of Henrik Kjaer Hansen

Companies	Position	End
OREXO AB	Director/Board Member	2023-10-26
Xellia Pharmaceuticals AS Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Develops, manufactures and supplies pharmaceutical drugs	Director/Board Member	-
Moelis & Co. (UK) LLP Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services	Corporate Officer/Principal	-

See the detail of Henrik Kjaer Hansen's experience

Training of Henrik Kjaer Hansen

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Henrik Kjaer Hansen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	8
Orexo AB Orexo AB Pharmaceuticals: MajorHealth Technology Manufactures and commercializes pharmaceutical products	Health Technology
Copenhagen Business School Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Xellia Pharmaceuticals AS Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Develops, manufactures and supplies pharmaceutical drugs	Health Technology
Sonion A/S Sonion A/S Medical SpecialtiesHealth Technology Design and manufactures micro-acoustic and micro-mechanical components for hearing instruments, in-ear earphones and earphones	Health Technology
Novo Principal Investments Novo Principal Investments Investment ManagersFinance Novo Principal invests in public and private companies located across Europe and North America. The firm focuses on companies operating in the fields of healthcare and life science sectors. It provides financing for later stage capital requirements.	Finance
Moelis & Co. (UK) LLP Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services	Finance
Novo Holdings A/S (Investment Company) Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings-IC aims to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. The firm invests in almost all life science segments including pharmaceuticals, biotechnology, medical technology, healthcare services and industrial BioSolutions. Outside of the life sciences they invest in a diversified portfolio of equities, fixed income, real assets and alternatives.	Finance
WCG Clinical, Inc. WCG Clinical, Inc. BiotechnologyHealth Technology Provides clinical research services	Health Technology